ATE411321T1 - Wasserlösliche rapamycin-ester - Google Patents
Wasserlösliche rapamycin-esterInfo
- Publication number
- ATE411321T1 ATE411321T1 AT01970890T AT01970890T ATE411321T1 AT E411321 T1 ATE411321 T1 AT E411321T1 AT 01970890 T AT01970890 T AT 01970890T AT 01970890 T AT01970890 T AT 01970890T AT E411321 T1 ATE411321 T1 AT E411321T1
- Authority
- AT
- Austria
- Prior art keywords
- water soluble
- soluble rapamycin
- rapamycin esters
- esters
- hydroxyesters
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23377600P | 2000-09-19 | 2000-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE411321T1 true ATE411321T1 (de) | 2008-10-15 |
Family
ID=22878646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01970890T ATE411321T1 (de) | 2000-09-19 | 2001-09-13 | Wasserlösliche rapamycin-ester |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6432973B1 (de) |
| EP (1) | EP1319008B1 (de) |
| JP (1) | JP2004509898A (de) |
| CN (1) | CN1222529C (de) |
| AT (1) | ATE411321T1 (de) |
| AU (1) | AU2001290841A1 (de) |
| BR (1) | BR0113975A (de) |
| CA (1) | CA2421485A1 (de) |
| DE (1) | DE60136200D1 (de) |
| DK (1) | DK1319008T3 (de) |
| ES (1) | ES2313983T3 (de) |
| MX (1) | MXPA03002258A (de) |
| WO (1) | WO2002024706A2 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2349458T3 (es) * | 2000-01-14 | 2011-01-03 | The Trustees Of The University Of Pennsylvania | Derivados o-metilados de rapamicina para aliviar e inhibir trastornos. |
| US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| WO2002085908A1 (en) | 2001-04-24 | 2002-10-31 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| JP4814520B2 (ja) * | 2002-05-15 | 2011-11-16 | エンドサイト，インコーポレイテッド | ビタミン−マイトマイシン結合体 |
| EP1553940B1 (de) * | 2002-07-30 | 2008-02-13 | Wyeth | Parenterale formulierungen mit einem rapamycin hydroxyester |
| EP1546369A4 (de) * | 2002-08-12 | 2007-01-17 | Univ Michigan | Diagnose und behandlung von krankheiten durch defekte im tuberösen sklerosepfad |
| EP2517729A3 (de) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate |
| AU2004232308A1 (en) * | 2003-04-23 | 2004-11-04 | Wyeth Holdings Corporation | PEG-wortmannin conjugates |
| AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
| WO2005053744A1 (en) * | 2003-11-26 | 2005-06-16 | Entelos, Inc. | TREATMENT OF RHEUMATOID ARTHRITIS WITH HYPOXIA-INDUCIBLE FACTOR 1α ANTAGONISTS |
| AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
| CA2562952A1 (en) | 2004-04-14 | 2005-11-10 | Wyeth | Regiospecific synthesis of rapamycin 42-ester derivatives |
| WO2005106007A1 (en) * | 2004-04-27 | 2005-11-10 | Wyeth | Labeling of rapamycin using rapamycin-specific methylases |
| WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| CN101137659A (zh) * | 2005-03-07 | 2008-03-05 | 惠氏公司 | 42-o-（2-羟基）乙基-雷帕霉素的氧杂环庚烷异构体 |
| US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
| EP1948240A2 (de) * | 2005-08-19 | 2008-07-30 | Endocyte, Inc. | Liganden-konjugate von vinca-alkaloiden, analoga und derivaten |
| WO2007022494A2 (en) * | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Multi-drug ligand conjugates |
| AU2006322030A1 (en) * | 2005-12-07 | 2007-06-14 | Wyeth | Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry |
| BRPI0619578A2 (pt) * | 2005-12-07 | 2011-10-04 | Wyeth Corp | processo para preparar um 42-éster de rapamicina, composto, método para isolar o boronato do 42-éster de rapamicina bruto a partir do licor mãe, método para purificação de um boronato do 42-éster de rapamicina, e, boronato de cci-779 |
| WO2007067565A1 (en) | 2005-12-07 | 2007-06-14 | Wyeth | Process for the preparation of purified crystalline cci-779 |
| US7605257B2 (en) * | 2006-03-07 | 2009-10-20 | Wyeth | Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
| US20080207671A1 (en) * | 2006-07-31 | 2008-08-28 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| WO2008094181A2 (en) * | 2007-02-01 | 2008-08-07 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
| US20100104626A1 (en) * | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| NZ580132A (en) * | 2007-03-14 | 2012-11-30 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins to vitamins |
| EP3569251A1 (de) | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Konjugate mit hydrophilen spacern/linkern |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| EP2209374B1 (de) | 2007-10-25 | 2014-12-03 | Endocyte, Inc. | Tubulysine und verfahren zu ihrer herstellung |
| CN101676291B (zh) * | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| KR20150070318A (ko) | 2012-10-16 | 2015-06-24 | 엔도사이트, 인코포레이티드 | 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법 |
| CN107949566B (zh) | 2016-05-10 | 2021-09-28 | 浙江海正药业股份有限公司 | 水溶性雷帕霉素类衍生物 |
| CN110314236A (zh) * | 2018-03-29 | 2019-10-11 | 天津键凯科技有限公司 | 聚乙二醇与雷帕霉素的结合物及其用途 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4375464A (en) | 1981-11-19 | 1983-03-01 | Ayerst, Mckenna & Harrison Inc. | Antibiotic AY24,668 and process of preparation |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| JP2631710B2 (ja) | 1988-08-16 | 1997-07-16 | 日本ヘキスト・マリオン・ルセル株式会社 | ピラノ〔ｆ〕キノリノン誘導体及び該化合物を有効成分とする医薬組成物 |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5023263A (en) | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| PT98990A (pt) * | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5130307A (en) * | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
| US5233036A (en) | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
| US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5093338A (en) | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5102876A (en) | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| ES2084940T3 (es) | 1991-06-18 | 1996-05-16 | American Home Prod | Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. |
| IL102414A (en) | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Medicinal preparations for the treatment of ocular inflammation, containing rapamycin |
| US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| ES2148224T3 (es) | 1992-03-30 | 2000-10-16 | American Home Prod | Formulacion de rapamicina para inyecciones intravenosas. |
| US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5411967A (en) | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5480989A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5480988A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5262423A (en) | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| WO1994025072A1 (en) * | 1993-04-23 | 1994-11-10 | American Home Products Corporation | Rapamycin conjugates and antibodies |
| US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
| US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5616588A (en) | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
| IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5516770A (en) | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| US5385910A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| US5385909A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
| US5389639A (en) | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5463048A (en) | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
| US5491231A (en) | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
-
2001
- 2001-09-13 JP JP2002529116A patent/JP2004509898A/ja not_active Withdrawn
- 2001-09-13 MX MXPA03002258A patent/MXPA03002258A/es active IP Right Grant
- 2001-09-13 CN CNB018159117A patent/CN1222529C/zh not_active Expired - Fee Related
- 2001-09-13 EP EP01970890A patent/EP1319008B1/de not_active Expired - Lifetime
- 2001-09-13 WO PCT/US2001/028575 patent/WO2002024706A2/en active Application Filing
- 2001-09-13 CA CA002421485A patent/CA2421485A1/en not_active Abandoned
- 2001-09-13 AT AT01970890T patent/ATE411321T1/de not_active IP Right Cessation
- 2001-09-13 BR BR0113975-4A patent/BR0113975A/pt not_active IP Right Cessation
- 2001-09-13 AU AU2001290841A patent/AU2001290841A1/en not_active Abandoned
- 2001-09-13 DK DK01970890T patent/DK1319008T3/da active
- 2001-09-13 DE DE60136200T patent/DE60136200D1/de not_active Expired - Fee Related
- 2001-09-13 ES ES01970890T patent/ES2313983T3/es not_active Expired - Lifetime
- 2001-09-18 US US09/954,782 patent/US6432973B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6432973B1 (en) | 2002-08-13 |
| JP2004509898A (ja) | 2004-04-02 |
| WO2002024706A3 (en) | 2002-10-10 |
| MXPA03002258A (es) | 2003-06-24 |
| US20020055518A1 (en) | 2002-05-09 |
| DE60136200D1 (de) | 2008-11-27 |
| ES2313983T3 (es) | 2009-03-16 |
| CN1222529C (zh) | 2005-10-12 |
| WO2002024706A2 (en) | 2002-03-28 |
| CA2421485A1 (en) | 2002-03-28 |
| DK1319008T3 (da) | 2009-02-09 |
| EP1319008A2 (de) | 2003-06-18 |
| CN1460108A (zh) | 2003-12-03 |
| EP1319008B1 (de) | 2008-10-15 |
| AU2001290841A1 (en) | 2002-04-02 |
| BR0113975A (pt) | 2003-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE411321T1 (de) | Wasserlösliche rapamycin-ester | |
| WO2002028866A3 (en) | Hydroxyesters of 7-desmethylrapamycin | |
| WO2002028867A3 (en) | Ethers of 7-desmethylrapamycin for use in immunosuppression | |
| WO2002026746A3 (en) | 1-oxorapamycins | |
| BR0211986A (pt) | 29-enóis de rapamicina | |
| MXPA04001523A (es) | Dialdehidos de rapamicina. | |
| ATE349976T1 (de) | Mikrostruktur-stentstruktur | |
| CO5611160A2 (es) | Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos | |
| DK1131065T3 (da) | Diakyldumarater til behandling af autoimmunsygdomme | |
| ES2115255T3 (es) | Derivados de rapamicina con el anillo estabilizado en c-22. | |
| BRPI0307673A2 (pt) | métodos de tratar doença vascular. | |
| WO2004031129A3 (en) | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | |
| EP1450819A4 (de) | Verfahren und zusammensetzungen zur prävention und behandlung von entzündlichen erkrankungen, autoimmunkrankheiten und transplantat-abstossungsreaktionen | |
| NO20006113D0 (no) | Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer | |
| ATE398188T1 (de) | Für akzessorische hiv proteine kodierende dna impfstoffe | |
| ITTO20010517A0 (it) | Cellule progenitrici vascolari umane. | |
| HK1071079A1 (en) | Use of soluble fgl2 as an immunosuppressant | |
| NO20022101D0 (no) | Peptider for behandling av erektil dysfunksjon | |
| ECSP045161A (es) | Piperidin-2,6-diona sustituida con heterociclo en la posición 3 | |
| FR2856598B1 (fr) | Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale | |
| RU2005111870A (ru) | Пептид, обладающий антикоагулянтной, фибриндеполимеризационной, антитромботической и фибринолитической активностями | |
| WO2004069142A3 (en) | Anti-candida agents for the treatment of prion diseases | |
| ECSP034578A (es) | Derivados de indolilmaleimida como inhibidores de proteina de cinasa c | |
| AU2002348160A1 (en) | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |